文献速递肺栓塞与肺血管病

吸入型sGC激活剂mosliciguat治疗PAH/CTEPH的1b期ATMOS试验

Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH.
PubMed 文献 · Thorax · 2026-09-11

ATMOS为开放标签、非随机1b期试验,评估单次递增剂量吸入mosliciguat在肺动脉高压或慢性血栓栓塞性肺高血压患者中的效果。38例受试者中,符合方案集(n=20)显示各剂量组PVR峰值较基线下降,且多持续3小时;不良事件多为轻度,未见体循环血管阻力或血压的安全性相关变化。

要点

  • 吸入mosliciguat在PAH/CTEPH患者中显示持续且具临床意义的PVR下降。
  • 不良事件多为轻度,最常见为头痛、氧饱和度下降和疲劳。
  • 未见体循环血管阻力或血压的安全性相关变化。

核心结论

  • Mosliciguat在肺高血压患者中安全性良好,并持续降低肺血管阻力。

研究设计与样本

  • ATMOS为开放标签、非随机1b期试验,评估单次递增剂量吸入mosliciguat。
  • 38例肺动脉高压或慢性血栓栓塞性肺高血压患者接受mosliciguat。
  • 符合方案集(PPS,n=20)纳入NO无反应且基线PVR≥5 Wood单位的受试者(每剂量n=4)。
  • 药效动力学集(PDS,n=37)纳入NO反应性受试者。
  • 5例PPS受试者接受背景治疗洗脱≥24小时。

主要发现

  • PPS中0.24 mg剂量组PVR峰值较基线平均下降21.0%(95%CI 31.6%至10.4%)。
  • PPS中0.48 mg剂量组PVR峰值较基线平均下降16.1%(95%CI 32.8%至-0.7%)。
  • PPS中1.0 mg剂量组PVR峰值较基线平均下降25.9%(95%CI 60.3%至-8.4%)。
  • PPS中2.0 mg剂量组PVR峰值较基线平均下降38.1%(95%CI 55.9%至20.3%)。
  • PPS中4.0 mg剂量组PVR峰值较基线平均下降36.3%(95%CI 48.3%至24.4%),且多持续3小时观察期;PDS中见类似效应。

关键数值与推荐

  • PPS纳入标准为NO无反应且基线PVR≥5 Wood单位。
  • 不良事件多为轻度,最常见头痛(3/38,7.9%)、氧饱和度下降和疲劳(各2/38,5.3%)。
  • 未见体循环血管阻力或血压的安全性相关变化。

临床怎么用

  • 吸入mosliciguat可能作为PAH/CTEPH的肺靶向血管扩张治疗选择,需进一步试验验证。

局限性

  • 非随机、开放标签设计。
  • 样本量小(PPS n=20,每剂量n=4)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mosliciguat, a soluble guanylate cyclase (sGC) activator, is designed for lung-targeted delivery via dry powder inhalation. Nitric oxide (NO) binds sGC's prosthetic heme group, catalysing cyclic guanosine monophosphate (cGMP) production, resulting in increased vasodilation, reduced inflammation/apoptosis, reverse vascular remodelling and antifibrotic effects. sGC is redox sensitive, losing heme in pulmonary hypertension (PH) oxidative stress conditions. Mosliciguat's novel 'activator' mechanism directly binds the sGC heme-binding pocket to induce cGMP, allowing it to target NO-insensitive heme-free sGC, potentially rescuing additional enzymatic activity. METHODS: A Proof-of-Concept Trial of Inhaled Mosliciguat, a First-in-Class Soluble Guanylate Cyclase Activator (ATMOS; non-randomised, open-label phase 1b trial) assessed single-dose escalation of mosliciguat in participants with pulmonary arterial hypertension or chronic thromboembolic PH. 38 participants received mosliciguat. The per protocol set (PPS, n=20) included NO-non-responsive participants with baseline pulmonary vascular resistance (PVR) ≥5 Wood units (n=4/dose). The pharmacodynamic set (PDS, n=37) included NO-responsive participants. Five PPS participants underwent a ≥24-hour washout from background therapy. RESULTS: In the PPS, doses of 0.24, 0.48, 1.0, 2.0 and 4.0 mg resulted in mean peak per cent PVR reductions from baseline (95% CI) of 21.0% (31.6% to 10.4%), 16.1% (32.8% to -0.7%), 25.9% (60.3% to -8.4%), 38.1% (55.9% to 20.3%) and 36.3% (48.3% to 24.4%), respectively, and generally persisted over the 3-hour observation period. Similar effects were seen in the PDS. The majority of adverse events were mild; most frequently reported were headache (n=3/38; 7.9%), decreased oxygen saturation and fatigue (n=2/38; 5.3% each). No safety-relevant changes were seen in systemic vascular resistance or blood pressure. CONCLUSIONS: Mosliciguat demonstrated a favourable safety profile and sustained, clinically meaningful reductions in PVR in participants with PH. TRIAL REGISTRATION NUMBER: NCT03754660.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Ghofrani HA, Leuchte HH, Al-Hiti H, et al. Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH. Thorax. 2026. PMID: 42728065. doi:10.1136/thorax-2025-224583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。